PRODH/POX-Dependent Celecoxib-Induced Apoptosis in MCF-7 Breast Cancer.

PRODH/POX apoptosis breast cancer proline

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
29 Aug 2021
Historique:
received: 23 07 2021
revised: 24 08 2021
accepted: 26 08 2021
entrez: 28 9 2021
pubmed: 29 9 2021
medline: 29 9 2021
Statut: epublish

Résumé

Celecoxib (Cx), an inhibitor of cyclooxygenase 2, induces apoptosis of cancer cells. However, the mechanism of the chemopreventive effect remains not fully understood. We aimed to investigate the role of PRODH/POX that is involved in the regulation of apoptosis induced by celecoxib. MCF-7 breast cancer cell line and the corresponding MCF-7 cell line with silenced PRODH/POX (MCF-7

Identifiants

pubmed: 34577574
pii: ph14090874
doi: 10.3390/ph14090874
pmc: PMC8471327
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Uniwersytet Medyczny w Bialymstoku
ID : N/ST/ZB/18/001/2227

Références

Molecules. 2020 Oct 12;25(20):
pubmed: 33053735
Oncotarget. 2018 Feb 9;9(17):13748-13757
pubmed: 29568391
Clin Chim Acta. 2011 Sep 18;412(19-20):1814-20
pubmed: 21699887
Mol Cell Biochem. 2020 Mar;466(1-2):35-44
pubmed: 31933109
Arthritis Res Ther. 2008;10(5):R111
pubmed: 18789153
Carcinogenesis. 2005 Aug;26(8):1335-42
pubmed: 15817612
Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):8983-8
pubmed: 22615405
Biochemistry. 1971 Mar 16;10(6):988-94
pubmed: 4323854
Oncogene. 2020 Mar;39(11):2358-2376
pubmed: 31911619
J Immunother Cancer. 2018 Dec 13;6(1):148
pubmed: 30545412
Int J Mol Sci. 2021 Jan 19;22(2):
pubmed: 33477820
Bratisl Lek Listy. 2016;117(8):480-5
pubmed: 27546702
Front Cell Dev Biol. 2021 Jan 12;8:603837
pubmed: 33511116
Antioxid Redox Signal. 2019 Feb 1;30(4):635-649
pubmed: 28990419
Nat Commun. 2017 Jul 07;8:16031
pubmed: 28685754
Pharmacogenet Genomics. 2012 Apr;22(4):310-8
pubmed: 22336956
Cancer Cell Int. 2012 Dec 19;12(1):53
pubmed: 23249419
J Cell Biochem. 2009 Jul 1;107(4):759-68
pubmed: 19415679
Nat Commun. 2017 May 11;8:15267
pubmed: 28492237
Sci Rep. 2015 Nov 24;5:17206
pubmed: 26598224
Elife. 2020 Oct 14;9:
pubmed: 33052098
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cell Physiol Biochem. 2017;43(2):670-684
pubmed: 28942439
Cancer Res. 2009 Aug 15;69(16):6414-22
pubmed: 19654292
Endocrinology. 1989 Feb;124(2):964-70
pubmed: 2463909
Int J Breast Cancer. 2011;2011:595092
pubmed: 22295229
Cell Cycle. 2009 Oct 15;8(20):3243-5
pubmed: 19806017
J Clin Oncol. 2005 Jan 10;23(2):254-66
pubmed: 15637389
Oncogene. 2006 Sep 14;25(41):5640-7
pubmed: 16619034
Amino Acids. 2021 Apr 5;:
pubmed: 33818628
Int J Cancer. 2008 Mar 15;122(6):1435-40
pubmed: 17999410
Biofactors. 2016 Jul 8;42(4):341-8
pubmed: 27040799
Cell Death Differ. 2005 Nov;12(11):1390-7
pubmed: 15905877
Cancers (Basel). 2020 Jan 06;12(1):
pubmed: 31935820

Auteurs

Magdalena Misiura (M)

Department of Analysis and Bioanalysis of Medicines, Medical University of Bialystok, Kilińskiego1, 15-089 Bialystok, Poland.

Ilona Ościłowska (I)

Department of Medicinal Chemistry, Medical University of Bialystok, Kilińskiego 1, 15-089 Bialystok, Poland.

Katarzyna Bielawska (K)

Department of Analysis and Bioanalysis of Medicines, Medical University of Bialystok, Kilińskiego1, 15-089 Bialystok, Poland.

Jerzy Pałka (J)

Department of Medicinal Chemistry, Medical University of Bialystok, Kilińskiego 1, 15-089 Bialystok, Poland.

Wojciech Miltyk (W)

Department of Analysis and Bioanalysis of Medicines, Medical University of Bialystok, Kilińskiego1, 15-089 Bialystok, Poland.

Classifications MeSH